We use cookies to help provide you with the best possible online experience.
By using this site, you agree that we may store and access cookies on your device. Cookie policy.
Cookie settings.
Functional Cookies
Functional Cookies are enabled by default at all times so that we can save your preferences for cookie settings and ensure site works and delivers best experience.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Covid Vaccinations
Eligible groups for autumn 2025
The Joint Committee on Vaccination and Immunisation (JCVI) has updated its advice for the autumn 2025 COVID-19 vaccination programme. The focus of the programme is shifting towards targeted vaccination of those at highest risk of serious disease.
For autumn 2025, COVID-19 vaccination will be offered to:
- Adults aged 75 years and ove
- Residents in care homes for older adult
- Individuals who are immunosuppressed aged 6 months and over
This represents a change from the autumn 2024 programme, which also included adults aged 65 to 74 and all those aged 6 months and over in a clinical risk group.
Immunosuppression due to disease or treatment, including:
- Those undergoing chemotherapy or radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients
- Genetic disorders affecting the immune system (e.g. deficiencies of IRAK-4 or NEMO, complement disorder, SCID)
- Those with haematological malignancy, including leukaemia and lymphoma & anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma
- Those receiving immunosuppressive or immunomodulating biological therapy
- Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults.
- Those receiving any dose of non-biological oral immune modulating drugs e.g. methotrexate, azathioprine, 6-mercaptopurine or mycophenolate
- Those with auto-immune diseases who may require long term immunosuppressive treatments for conditions including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, scleroderma and psoriasis.
- Children who are about to receive planned immunosuppressive therapy should be considered for vaccination prior to commencing therapy.
Please note
In line with JCVI advice, frontline health and social care workers (HSCWs) and staff working in care homes for older adults will not be eligible for COVID-19 vaccination under the national programme for autumn 2025.
Published: Oct 8, 2025